Spots Global Cancer Trial Database for Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis

Official Title: Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis

Study ID: NCT03914638

Conditions

Myasthenia Gravis

Interventions

Salbutamol 4Mg Tablet

Placebo oral capsule

Study Description

Brief Summary: This study examines the effect of adjuvant therapy with the oral beta-agonist Salbutamol in patients with generalized myasthenia gravis on stable standard of care having residual symptoms.

Detailed Description: Myasthenia Gravis (MG) causes various degrees of increased muscular fatigue and ocular, bulbar, respiratory and extremity symptoms. Residual symptoms often remain despite treatment with acetylcholinesterase inhibitors and immunosuppressive agents. Escalation of immunosuppressive treatment may provide additional benefit but is associated with potentially severe side effects, and high economic costs. Treatment with beta-agonists has been investigated in animal models of MG, and in small, randomized pilot studies of generalized MG. Adjuvant therapy with oral beta-agonists in MG may be safe and cheap and may improve symptoms. The trial will examine the tolerability and efficacy of adjuvant therapy with the oral beta-agonist Salbutamol in patients with generalized myasthenia gravis on stable standard of care having residual symptoms. Present study is an investigator-initiated, randomized, placebo-controlled, rater and subject-blinded crossover study. Study consists of Screening Period (4 weeks), Treatment Period 1 (8 weeks), Washout Period (4 weeks), Treatment Period 2 (8 weeks).